Revenue
$163.58M
Fiscal year ended 2026-06-30Operating income
-$6.97M
Fiscal year ended 2026-06-30Free cash flow
Unavailable
Fiscal year ended 2026-06-30OPKO HEALTH, INC. (OPK) reported revenue of $163.58M and net income of -$8.42M for the fiscal year ended 2026-06-30. This page shows 10 annual periods of income statement, balance sheet and cash flow figures normalized from OPKO HEALTH, INC.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.
Income
| Metric | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $163.58M | $124.20M | $148.45M | $151.67M | $156.81M | $149.95M | $183.64M | $173.63M | $182.19M | $173.69M |
| Cost of revenue | $83.56M | $78.44M | $84.42M | $101.78M | $107.40M | $107.33M | $98.98M | $133.50M | $130.53M | $131.62M |
| Gross profit | $80.02M | $45.76M | $64.02M | $49.89M | $49.40M | $42.62M | $84.66M | $40.13M | $51.65M | $42.07M |
| Operating income | -$6.97M | -$51.02M | -$38.32M | $48.06M | -$59.98M | -$67.17M | -$33.14M | -$67.17M | -$61.67M | -$71.47M |
| Net income | -$8.42M | -$54.85M | -$31.26M | $21.63M | -$148.44M | -$67.61M | $14.03M | $24.89M | -$10.30M | -$81.84M |
| Research & development | $33.17M | $29.20M | $32.77M | $30.08M | $30.34M | $30.84M | $30.42M | $28.77M | $24.08M | $21.94M |
| Weighted-average diluted shares | shares 755.27M | shares 758.88M | Unavailable | shares 779.92M | shares 788.01M | shares 671.58M | Unavailable | shares 998.36M | shares 697.21M | Unavailable |
| Pretax income | -$13.40M | -$60.96M | -$46.90M | $41.43M | -$162.52M | -$73.37M | $34.98M | $48.42M | -$10.58M | -$83.18M |
| Income tax expense | -$4.98M | -$6.11M | -$15.66M | $19.80M | -$14.08M | -$5.77M | $20.95M | $23.53M | -$280.00K | -$1.35M |
| Diluted EPS | $-0.01 | $-0.07 | $-0.04 | $0.03 | $-0.19 | $-0.10 | $0.01 | $0.03 | $-0.01 | $-0.12 |
| Selling, general & administrative | $52.92M | $48.61M | $50.52M | $53.80M | $59.60M | $59.09M | $67.03M | $98.20M | $68.82M | $70.17M |
| General & administrative | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Selling & marketing | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
Balance
| Metric | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $300.76M | $331.86M | $364.41M | $411.97M | $267.28M | $428.83M | $426.58M | $400.08M | $40.58M | $75.64M |
| Total assets | $1.83B | $1.86B | $1.93B | $2.00B | $1.97B | $2.13B | $2.20B | $2.26B | $1.98B | $1.97B |
| Current assets | $500.24M | $535.36M | $581.88M | $627.13M | $583.33M | $737.60M | $662.09M | $629.64M | $357.98M | $391.30M |
| Total liabilities | $645.29M | $652.19M | $663.98M | $690.02M | $676.08M | $816.66M | $834.76M | $852.69M | $584.55M | $721.21M |
| Current liabilities | $149.37M | $148.38M | $146.68M | $169.32M | $171.18M | $295.85M | $193.10M | $211.66M | $219.55M | $204.34M |
| Total equity incl. NCI | $1.18B | $1.20B | $1.27B | $1.31B | $1.30B | $1.31B | $1.37B | $1.40B | $1.40B | $1.25B |
| Temporary (mezzanine) equity | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Inventory | $61.85M | $64.40M | $65.82M | $64.95M | $66.34M | $64.00M | $56.80M | $59.41M | $60.15M | $59.37M |
| Accounts receivable | $81.89M | $79.64M | $90.26M | $94.58M | $99.38M | $96.15M | $118.02M | $106.58M | $105.31M | $111.37M |
| Goodwill | $481.52M | $482.27M | $484.29M | $484.03M | $484.18M | $476.67M | $529.25M | $535.87M | $530.11M | $530.62M |
| Long-term debt | $1.78M | $2.01M | $2.26M | $2.51M | $2.77M | $2.83M | $3.00M | $3.53M | $3.68M | $4.04M |
| Accounts payable | $50.04M | $44.18M | $41.10M | $50.83M | $56.68M | $59.37M | $47.07M | $62.72M | $82.24M | $71.16M |
Cash flow
| Metric | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$43.50M | -$19.31M | -$25.92M | -$34.65M | -$83.42M | -$34.55M | -$44.41M | -$77.08M | -$26.44M | -$35.57M |
| Capital expenditures | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Investing cash flow | $15.54M | -$1.80M | -$2.05M | $194.65M | -$2.83M | $40.53M | $115.99M | $247.78M | -$7.16M | -$4.40M |
| Financing cash flow | -$13.03M | -$5.16M | -$18.34M | -$16.21M | -$79.49M | -$4.02M | -$40.47M | $206.14M | -$2.12M | $20.61M |
| Net change in cash | -$41.14M | -$27.18M | -$46.13M | $143.48M | -$164.28M | $4.06M | $25.55M | $379.49M | -$35.06M | -$20.24M |
| Stock-based compensation | $2.20M | $2.74M | $2.92M | $3.00M | $2.20M | $2.62M | $3.06M | $2.80M | $2.60M | $2.59M |
| Common dividends paid | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Common share repurchases | $13.02M | $4.77M | $13.51M | $15.28M | $18.26M | $0 | $16.46M | $23.76M | $0 | $50.00M |
| Depreciation & amortization | $22.41M | $22.20M | $22.37M | $22.74M | $23.03M | $23.49M | $24.04M | $24.16M | $24.16M | $25.82M |
Derived
| Metric | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Free cash flow | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Gross margin | 48.9% | 36.8% | 43.1% | Unavailable | 31.5% | 28.4% | 46.1% | Unavailable | Unavailable | Unavailable |
| Operating margin | -4.3% | -41.1% | -25.8% | Unavailable | -38.3% | -44.8% | -18.0% | Unavailable | Unavailable | Unavailable |
| FCF margin | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| SBC / revenue | 1.3% | 2.2% | 2.0% | Unavailable | 1.4% | 1.7% | 1.7% | Unavailable | Unavailable | Unavailable |
| Current ratio | 3.35x | 3.61x | 3.97x | 3.70x | 3.41x | 2.49x | 3.43x | 2.97x | 1.63x | 1.91x |
| Revenue YoY growth | 4.3% | -17.2% | -19.2% | -12.6% | -13.9% | -13.7% | 1.0% | -2.8% | -31.4% | -26.9% |
| Net margin | -5.1% | -44.2% | -21.1% | 14.3% | -94.7% | -45.1% | 7.6% | 14.3% | -5.7% | -47.1% |
| R&D / revenue | 20.3% | 23.5% | 22.1% | Unavailable | 19.3% | 20.6% | 16.6% | Unavailable | Unavailable | Unavailable |
| CapEx / revenue | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Long-term debt / equity | 0.00x | Unavailable | 0.00x | 0.00x | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Effective tax rate | Unavailable | Unavailable | Unavailable | 47.8% | Unavailable | Unavailable | 59.9% | 48.6% | Unavailable | Unavailable |
Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open OPK in the interactive workspace to inspect any figure back to its filing.
Source filings
10-Q/A · Filed 2026-08-28View SEC filing
10-Q/A · Filed 2026-08-28View SEC filing
10-Q · Filed 2026-07-27View SEC filing
10-Q · Filed 2026-04-28View SEC filing
10-K · Filed 2026-02-26View SEC filing
10-Q · Filed 2025-10-29View SEC filing
Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.